Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study
Authors
Keywords
Anakinra, Behçet’s disease, Canakinumab, Treatment, Uveitis
Journal
CLINICAL RHEUMATOLOGY
Volume 36, Issue 1, Pages 191-197
Publisher
Springer Nature
Online
2016-12-17
DOI
10.1007/s10067-016-3506-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial
- (2016) Jared E. Knickelbein et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study
- (2016) Antonio Vitale et al. CLINICAL RHEUMATOLOGY
- Management of Behçetʼs syndrome
- (2016) Yesim Ozguler et al. CURRENT OPINION IN RHEUMATOLOGY
- Safety and Efficacy of Gevokizumab in Patients with Behçet’s Disease Uveitis: Results of an Exploratory Phase 2 Study
- (2016) Ilknur Tugal-Tutkun et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study
- (2016) Antonio Vitale et al. Frontiers in Pharmacology
- Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease
- (2015) Luca Cantarini et al. AUTOIMMUNITY REVIEWS
- Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study
- (2015) Giacomo Emmi et al. CLINICAL RHEUMATOLOGY
- Local (topical and intraocular) therapy for ocular Adamantiades−Behçetʼs disease
- (2015) Claudia Fabiani et al. CURRENT OPINION IN OPHTHALMOLOGY
- Cutting Edge: IL-1 Receptor Signaling is Critical for the Development of Autoimmune Uveitis
- (2015) Chi-Keung Wan et al. JOURNAL OF IMMUNOLOGY
- Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease
- (2015) Ilaria Pagnini et al. RHEUMATOLOGY
- Pathogenesis of Behçet’s disease: autoinflammatory features and beyond
- (2015) Ahmet Gül Seminars in Immunopathology
- Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series
- (2014) Antonio Vitale et al. DERMATOLOGY
- Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy
- (2014) Francesco Caso et al. MEDIATORS OF INFLAMMATION
- Resistant Behçet Disease Responsive to Anakinra
- (2013) Costantino Botsios et al. ANNALS OF INTERNAL MEDICINE
- Anakinra treatment in drug-resistant Behcet’s disease: a case series
- (2013) Luca Cantarini et al. CLINICAL RHEUMATOLOGY
- The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α
- (2013) Monica Castrichini et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria
- (2013) et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease: Figure 1
- (2012) Serdal Ugurlu et al. ANNALS OF THE RHEUMATIC DISEASES
- Controversies in Behçet Disease
- (2012) Denis Wakefield et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study
- (2011) Ahmet Gül et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease
- (2009) Yelda Bilginer et al. CLINICAL RHEUMATOLOGY
- Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis
- (2009) Kaoru Takase et al. RHEUMATOLOGY INTERNATIONAL
- EULAR recommendations for the management of Behcet disease
- (2008) G Hatemi et al. ANNALS OF THE RHEUMATIC DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More